National
Bio-Thera wins China approval for Simponi biosimilar to treat autoimmune diseases
Source: Healthcaremea|
1 min read
The drug, which will be marketed under the brand name Ashuli, is the first biosimilar of Johnson & Johnson’s Simponi (golimumab) to receive marketing authorisation in China.